A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

Jan C. Drooger*, Harm van Tinteren, Steffen M. de Groot, Albert J. ten Tije, Hiltje de Graaf, Johanneke E A Portielje, Agnes Jager, Aafke Honkoop, Sabine C. Linn, Judith R. Kroep, Frans L G Erdkamp, Paul Hamberg, Alex L T Imholz, Quirine C. van Rossum-Schornagel, Joan B. Heijns, A. Elise van Leeuwen-Stok, Stefan Sleijfer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology